Last updated on November 2019

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)

Brief description of study

A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.

Detailed Study Description

Open label phase I, dose escalation trial for patients with triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated with residual disease (after neoadjuvant chemotherapy).

Clinical Study Identifier: NCT03109080

Find a site near you

Start Over

Institut Curie

Paris, France
  Connect »